Private equity firm Antin Infrastructure Partners (Euronext Paris:ANTIN) announced on Thursday that it has agreed to acquire Emsere from Dutch family investment platform Gryphion.
Emsere, headquartered in Leiden in the Netherlands, is a medical equipment rental specialist providing clinical trial equipment and logistics solutions to pharmaceutical companies and contract research organisations (CROs) globally.
Founded in 1996, Emsere manages over 13,000 pieces of equipment and delivers to more than 100 countries, serving six of the top 10 global pharmaceutical companies and seven of the top 10 CROs. Its portfolio includes centrifuges, imaging devices, cardiovascular and respiratory monitors, and cardio-pulmonary exercise testing equipment.
The company operates in the growing clinical trial equipment rental market, addressing demand for outsourced, complex, and regulatory-compliant solutions delivered at scale. Emsere's services allow clients to focus on scientific and clinical execution while avoiding capital expenditure and logistical coordination.
Antin's investment marks the eighth for its EUR2.2bn Mid Cap Fund I and continues its strategy of scaling health and medical infrastructure companies in Europe and North America. Emsere's CEO Patrice Gerard and senior management will co-invest alongside Antin.
The transaction is expected to close in the first quarter of 2026.
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
GSK agrees US pricing framework to expand access to respiratory medicines
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
bioMérieux launches equine endocrinology tests to expand point-of-care diagnostics
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Neola Medical secures US patent for disposable lung monitoring probes
Spinogenix reports approval of 'tazbentetol' as non-proprietary name for SPG302
Polarean expands XENOVIEW 3T Coil access with Philips compatibility
Immedica gets UAE approval for Zepzelca maintenance treatment